drugset / Trial / NCT04097951

HDDO-1801 Intervention Trial

NCT04097951

Phase 1 Unknown 36 enrolled Hyundai Pharmaceutical Co., LTD.
RandomizedCrossoverOpen-labelOther

Summary

A randomized, open-label, single-dose, 3-period, 6-sequence, 3-way crossover study

Timeline

Start
2019-11-08
Primary completion
2020-01-08
Completion
2020-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Bepotastine Small molecule Oral
Subject Montelukast Other / unclassified Oral